Correlated electrostatic mutations provide a reservoir of stability in HIV protease.

Abstract excerpt

HIV protease, an aspartyl protease crucial to the life cycle of HIV, is the target of many drug development programs. Though many protease inhibitors are on the market, protease eventually evades these drugs by mutating at a rapid pace and building drug resistance. The drug resistance mutations, called primary mutations, are often destabilizing to the enzyme and this loss of stability has to be compensated for....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Computer Simulation
• Share to Enzyme Stability
• Share to HIV Protease